Pharmacokinetics and metabolism of 1-(4-bromobenzyl)-1-(4-bromobenzyloxy) urea in vitro

LI Wen,MAI Xi,HU Xiao
2013-01-01
Abstract:Objective To investigate the pharmacokinetics of 1-(4 bromobenzyl)-1-(4-bromobenzyloxy) urea(HY-D11) in rats and metabolism of HY-D11 in rat liver microsome incubation system.Methods The HPLC analysis method of HY-D11 in biological sample was set up to investigate its pharmacokinetics after an oral dose of 66.7 mg· kg-1in rats.CYP1A inhibitor(α-naphthoflavone),CYP2B inhibitor(sertraline),CYP2C inhibitor(quercetin),CYP2D inhibitor(yohimbine),CYP2E inhibito(disulfiram) and CYP3A inhibitor(troleandomycin) were used to investigate their inhibitory effects on the metabolism of HY-D11.Results A stable and reliable HY-D11 samples detection method was established.The pharmacokinetic profiles of HY-D11 are described by two-compartment model legitimately.The t max is(3.67 ± 0.52) h,C max is(1.61 ± 0.13) mg·L-1,t 1 /2z is(3.66 ± 0.25) h,MRT 0-∞ is(7.05 ± 0.29) h.The metabolism of HY-D11 in liver microsome incubation solution showed the characteristic of enzyme kinetics.The α-naphthoflavone,sertraline,quercetin,yohimbine,and disulfiram did not have effect on HY-D11 metabolism in liver microsome incubation solution(P > 0.05).The troleandomycin reduced HY-D11 metabolism in liver microsome incubation solution( P < 0. 05). Conclusion The absorption and metabolism of HY-D11 are very rapid. The metabolism of HY- D11 in rats may be mediated by CYP3A.
What problem does this paper attempt to address?